The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B
Open accessAbstract
Increased interleukin‐6 (IL‐6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL‐6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case‐control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty‐seven patients developed HCC at a median follow‐up of 62 months (interquartile range: 41–110). Serum IL‐6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL‐6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL‐6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL‐6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high‐risk patients for HCC surveillance program. © 2009 UICC
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair
Jin, X., Zimmers, T. A., Perez, E. A., Pierce, R. H., Zhang, Z., & Koniaris, L. G. (2006) · Hepatology · doi:10.1002/hep.21087 · Cited by 173
Cited by
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
NF-κB and STAT3 – key players in liver inflammation and cancer
He, G., & Karin, M. (2011) · Cell Research · doi:10.1038/cr.2010.183 · Cited by 1,197
NF- B as a Critical Link Between Inflammation and Cancer
Karin, M. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000141 · Cited by 816
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
Wong, V. W.-S., Chan, S. L., Mo, F., Chan, T.-C., Loong, H. H.-F., Wong, G. L.-H., Lui, Y. Y.-N., Chan, A. T.-C., Sung, J. J.-Y., Yeo, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2675 · Cited by 502
Self-citationWong, G. L.-H., Chan, H. L.-Y., Mak, C. W.-H., Lee, S. K.-Y., Ip, Z. M.-Y., Lam, A. T.-H., Iu, H. W.-H., Leung, J. M.-S., Lai, J. W.-Y., Lo, A. O.-S., et al. (2013) · Hepatology · doi:10.1002/hep.26301 · Cited by 488
Self-citationDNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428
He, G., Yu, G.-Y., Temkin, V., Ogata, H., Kuntzen, C., Sakurai, T., Sieghart, W., Peck-Radosavljevic, M., Leffert, H. L., & Karin, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.048 · Cited by 427
Capece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., Zazzeroni, F., & Alesse, E. (2013) · BioMed Research International · doi:10.1155/2013/187204 · Cited by 408
The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Yang, J. D., Nakamura, I., & Roberts, L. R. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.007 · Cited by 390
Chew, V., Chen, J., Lee, D., Loh, E., Lee, J., Lim, K. H., Weber, A., Slankamenac, K., Poon, R. T. P., Yang, H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300509 · Cited by 359
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 260
The Inflammation and Liver Cancer
Bishayee, A. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_16 · Cited by 255
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Mechanisms linking pathogens-associated inflammation and cancer
Porta, C., Riboldi, E., & Sica, A. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.10.012 · Cited by 119
Nadph oxidase 1 in liver macrophages promotes inflammation and tumor development in mice
Liang, S., Ma, H.-Y., Zhong, Z., Dhar, D., Liu, X., Xu, J., Koyama, Y., Nishio, T., Karin, D., Karin, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.019 · Cited by 92
Naseem, S., Hussain, T., & Manzoor, S. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.01.002 · Cited by 72
Ahodantin, J., Bou-Nader, M., Cordier, C., Mégret, J., Soussan, P., Desdouets, C., & Kremsdorf, D. (2019) · Oncogene · doi:10.1038/s41388-018-0607-3 · Cited by 46
Metadata
- Authors
- Wong, V. W., Yu, J., Cheng, A. S., Wong, G. L., Chan, H., Chu, E. S., Ng, E. K., Chan, F. K., Sung, J. J., & Chan, H. L.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-03-06
- Volume
- 124
- Issue
- 12
- Pages
- 2766-2770
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2022969414
- Cited by
- 208
- References
- 1
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.